Tenofovir disoproxil fumarate for the treatment of chronic hepatitis B monoinfection

[Guest guest]

http://www.mdlinx.com/gastroenterology/newsl-article.cfm/3657647/ZZ6806553679256\

39220014/?news_id=511 & newsdt=062911 & subspec_id=144

Tenofovir disoproxil fumarate for the treatment of chronic hepatitis B

monoinfection

Hepatology International, 06/29/2011 Clinical Article

Seto WK et al. – Tenofovir disoproxil fumarate(TDF) has the makings of an

“ideal” first–line drug for the treatment of chronic hepatitis B(CHB).

• Initially developed for the treatment of HIV infection, early in vitro and

clinical observational studies had shown tenofovir disoproxil fumarate (TDF) to

be also active against CHB.

• Recent data from various multicenter phase 3 and 4 clinical trials have

confirmed TDF being able to achieve a high viral suppression in both NA-naive

and -experienced CHB patients.

• There are also emerging data on the efficacy of TDF in decompensated CHB

• Although there are in vitro studies identifying certain mutation loci

associated with a reduced susceptibility to TDF, there have so far been no

reports of virologic resistance to TDF in clinical studies.

• TDF has a favorable safety profile, although more long-term data would be

needed.

[Guest guest]

http://www.mdlinx.com/gastroenterology/newsl-article.cfm/3657647/ZZ6806553679256\

39220014/?news_id=511 & newsdt=062911 & subspec_id=144

Tenofovir disoproxil fumarate for the treatment of chronic hepatitis B

monoinfection

Hepatology International, 06/29/2011 Clinical Article

Seto WK et al. – Tenofovir disoproxil fumarate(TDF) has the makings of an

“ideal” first–line drug for the treatment of chronic hepatitis B(CHB).

• Initially developed for the treatment of HIV infection, early in vitro and

clinical observational studies had shown tenofovir disoproxil fumarate (TDF) to

be also active against CHB.

• Recent data from various multicenter phase 3 and 4 clinical trials have

confirmed TDF being able to achieve a high viral suppression in both NA-naive

and -experienced CHB patients.

• There are also emerging data on the efficacy of TDF in decompensated CHB

• Although there are in vitro studies identifying certain mutation loci

associated with a reduced susceptibility to TDF, there have so far been no

reports of virologic resistance to TDF in clinical studies.

• TDF has a favorable safety profile, although more long-term data would be

needed.